Kunzer Aaron R

TL;DR: Overall, this study shows that, with only a few fragment hits, multiple lead series can be generated for HSP90 due to the inherent flexibility of the active site, and ample opportunities exist to use these lead series in the development of clinically useful H SP90 inhibitors for the treatment of cancers.

TL;DR: In this paper, Nacylsulfonamide compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases were discussed.

TL;DR: In this paper, compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl1 protein are disclosed.

TL;DR: The use of fragment screening methods and structural biology are described to drive the discovery of novel MCL-1 inhibitors from two distinct structural classes that may serve as promising leads for medicinal chemistry optimization efforts.

TL;DR: The discovery and characterization of a small molecule binding site on the survivin surface distinct from the Smac peptide-binding site is described and may ultimately serve as a basis for the development of small molecule therapeutics acting via direct or allosteric disruption of binding events related to this poorly understood target.